Welcome to our dedicated page for CervoMed SEC filings (Ticker: CRVO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on CervoMed's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into CervoMed's regulatory disclosures and financial reporting.
ALAM JOHN J reported acquisition or exercise transactions in a Form 4 filing for CRVO. The filing lists transactions totaling 75,000 shares. Following the reported transactions, holdings were 75,000 shares.
Morgan Stanley and its affiliate Morgan Stanley Capital Services LLC have filed a Schedule 13G reporting beneficial ownership of CervoMed Inc. common stock. Morgan Stanley reports beneficial ownership of 473,681 shares, representing 5.1% of CervoMed’s common stock as of the event date.
Morgan Stanley Capital Services LLC reports beneficial ownership of 470,631 shares, also representing 5.1% of the class, with shared voting and dispositive power over these shares. The filing states the position was acquired and is held in the ordinary course of business and not for the purpose of changing or influencing control of CervoMed.
CervoMed Inc. reported that it has made an investor presentation available on its website under the “Investors – Events and Presentations” section. Company representatives may use this presentation in meetings and conferences with investors, analysts and others, with possible non-material updates over time.
The presentation is described as summary information meant to be read together with CervoMed’s other SEC filings and public announcements. The company states it has no obligation to update the presentation except as required by law, and clarifies that the information is being furnished under Regulation FD rather than filed, so it is not subject to certain Exchange Act liabilities nor automatically incorporated into other securities filings.
CervoMed Inc. officer reports open-market stock purchases
An officer of CervoMed Inc. (CRVO), serving as Chief Commercial and Business leader, reported buying company common stock in open-market transactions. On 11/17/2025, the officer purchased 3,500 shares at a price of $8.43 per share. On 11/18/2025, the officer purchased an additional 1,500 shares at $7.95 per share.
After these transactions, the officer beneficially owns a total of 15,000 shares of CervoMed common stock, held directly. The filing indicates that the reported transactions were regular stock purchases rather than option exercises or other derivative security activity.
CervoMed Inc. (CRVO) director and 10% owner reported open‑market purchases of common stock. On 11/17/2025, the reporting person bought 10,793 shares of CervoMed common stock at a weighted average price of $8.46 per share in open‑market transactions. On the same date, an additional 10,807 shares were purchased at a weighted average price of $8.46 per share in an individual retirement account held by the reporting person’s spouse. After these transactions, the reporting person beneficially owned 1,484,078 shares directly and 12,500 shares indirectly through the spouse’s IRA, including shares jointly held with the issuer’s President & Chief Executive Officer.
CervoMed Inc. (CRVO) reported insider share purchases by a senior executive. The company’s CFO, General Counsel and Secretary bought 1,000 shares of common stock on 11/17/2025 at $8.45 per share and 2,500 shares on 11/18/2025 at a weighted average price of $8.32 per share in open‑market transactions. Following these transactions, the reporting person beneficially owned 12,500 shares of CervoMed common stock directly.
The filing notes that the 2,500 shares purchased on 11/18/2025 were acquired at prices ranging from $8.26 to $8.38, with the weighted average price reported, and that detailed trade breakdowns are available upon request.
CervoMed Inc. (CRVO) reported insider share purchases by its CEO & President, who is also a director and 10% owner. On 11/17/2025, the reporting person bought 10,807 shares of common stock in open‑market transactions at a weighted average price of $8.46, with actual prices ranging from $8.39 to $8.46. Following this, the reporting person directly beneficially owned 1,484,078 shares.
On the same date, an additional 10,793 shares were purchased at a weighted average price of $8.46 (with prices from $8.38 to $8.50) for the reporting person’s spouse’s IRA, which is reported as indirect ownership of 12,500 shares. The ownership totals also include shares held jointly with the spouse and in a Roth IRA.
CervoMed Inc. (CRVO) reported insider share purchases by a major holder. A director and 10% owner bought 4,447 shares of common stock on 11/13/2025 at $7.51 per share in open-market transactions. On 11/14/2025, additional purchases included 1,707 shares at a weighted average price of $7.57 through the Sylvie Gregoire Roth IRA and 1,693 shares at a weighted average price of $7.55 through the John J. Alam Roth IRA.
After these transactions, the reporting person beneficially owned 1,471,578 shares of CervoMed common stock directly, with 1,693 shares held indirectly through a spouse's IRA. Some shares are held jointly with the reporting person's spouse, Dr. John Alam, the company's President & Chief Executive Officer and a member of the Board of Directors.
CervoMed Inc. (CRVO) reported insider buying by its CEO, President, director and 10% owner. On 11/13/2025, the reporting person bought 4,447 shares of common stock in open-market transactions at $7.51 per share. On 11/14/2025, additional open-market purchases included 1,693 shares at a weighted average price of $7.55 through the John J. Alam Roth IRA and 1,707 shares at a weighted average price of $7.57 through the Sylvie Gregoire Roth IRA. Following these transactions, 1,471,578 shares were held jointly by the reporting person and his spouse, Dr. Sylvie Gregoire, with separate Roth IRA holdings noted.
CervoMed Inc. (CRVO) reported an insider transaction in which its Chief Commercial and Business officer purchased 10,000 shares of common stock in open-market transactions on 11/14/2025 at a weighted average price of $7.57 per share. Following this transaction, the reporting person beneficially owns 10,000 shares, held directly.
According to the filing, the shares were bought in multiple open-market trades at prices ranging from $7.53 to $7.60 per share. The reporting person has undertaken to provide full details of the number of shares purchased at each separate price within this range upon request.